2-(carbethoxy)-3,3-dimethylbutyric acid | 83096-36-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(carbethoxy)-3,3-dimethylbutyric acid
• 英文别名: 2-tert-butyl-malonic acid monoethyl ester；2-(Ethoxycarbonyl)-3,3-dimethylbutanoic acid；2-ethoxycarbonyl-3,3-dimethylbutanoic acid
• CAS: 83096-36-0
• 化学式: C₉H₁₆O₄
• mdl: MFCD20638324
• 分子量: 188.224
• InChiKey: DBUFLUUYBYPRDP-UHFFFAOYSA-N

物化性质

• 沸点：
  205-210 °C(Press: 750 Torr)
• 密度：
  1.0144 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(carbethoxy)-3,3-dimethylbutyric acid 在 硫酸 、 sodium 作用下， 生成 (+/-)-α,α'-di-tert-butylsuccinic anhydride
  参考文献：
  名称：

  Benzodiazepines and anterior pituitary function

  摘要：

  Benzodiazepines (BDZ) are one of the most prescribed classes of drugs because of their marked anxiolytic, anticonvulsant, muscle relaxant and hypnotic effects. The pharmacological actions of BDZ depend on the activation of 2 specific receptors. The central BDZ receptor, present in several areas of the central nervous system (CNS), is a component of the GABA-A receptor, the activation of which increases GABAergic neurotransmission and is followed by remarkable neuroendocrine effects. The peripheral benzodiazepine receptors (PBR), structurally and functionally different from the GABA-A receptor, have been shown in peripheral tissues but also in the CNS, in both neurones and glial cells, and in the pituitary gland. BDZ receptors bind to a family of natural peptides called endozepines, firstly isolated from neurons and glial cells in the brain and then in several peripheral tissues as well. Endozelpines modulate several central and peripheral biological activities, including some neuroendocrine functions and synthetic BDZ are likely to mimic them, at least partially. BZD, especially alprazolam (AL), possess a clear inhibitory influence on the activity of the HPA axis in both animals and humans. This effect seems to be mediated at the hypothalamic and/or suprahypothalamic level via suppression of CRH. The strong negative influence of AL on hypothalamic-pituitary-adrenal (HPA) axis agrees with its peculiar efficacy in the treatment of panic disorders and depression. BZD have also been shown to increase GH secretion via mechanisms mediated at the hypothalamic or supra-hypothalamic level, though a pituitary action cannot be ruled out. Besides the impact on HPA and somatotrope function, BDZ also significantly affect the secretion of other pituitary hormones, such as gonadotropins and. PRL, probably acting through GABAergic mediation in the hypothalamus and/or in the pituitary gland. In all, BDZ are likely to represent a useful tool to investigate GABAergic activity and clarify its role in the neuroendocrine control of anterior pituitary function; their usefulness probably overrides what had been supposed before.

  DOI：

  10.1007/bf03345110
• 作为产物：
  描述：

  亚异丙基丙二酸二乙酯 在 copper(l) cyanide 作用下， 以 乙醚 为溶剂， 生成 2-(carbethoxy)-3,3-dimethylbutyric acid
  参考文献：
  名称：

  Evans, Andrew R.; Hafiz, Mushtaq; Taylor, Giles A., Journal of the Chemical Society. Perkin transactions I, 1984, # 6, p. 1241 - 1246

  摘要：

  DOI：

文献信息

• Conjugated ketenes: cyclopropyl, alkenyl, alkynyl, and acyl substituents
  作者：Annette D. Allen、Leyi Gong、Thomas T. Tidwell

  DOI：10.1021/ja00173a037

  日期：1990.8

  La preparation et les etudes de reactivite des alcynyl-, cyclopropyl-, et acylcetenes, de meme que les calculs sur les orbitales moleculaires suggerent que les substituants conjugues n'ont pas en general, d'effets stabilisants importants sur le cetene

  La制备和研究反应性炔基-，环丙基-，et acylcetenes，de meme que les calculs sur lesorbitalesmoleculaires suggerent que les substituants conjugues n'ont pas en general, d'effets stabilisants importants surle
• Nitration of α,β-unsaturated esters. Evidence for positive charge build-up adjacent to carbonyl carbon
  作者：Stuart A. Hewlins、John A. Murphy、Jian Lin、David E. Hibbs、Michael B. Hursthouse

  DOI：10.1039/a607170h

  日期：——

  Reactive intermediates formed in the nitration of certain α,β-unsaturated esters with nitronium tetrafluoroborate exhibit behaviour expected of highly reactive α-carbonyl cations. Three diagnostic reaction types have been observed which indicate the presence of these destabilised cations: (i) trapping in a Ritter reaction, (ii) cyclopropane formation from propyl cations, (iii) Wagner–Meerwein migration of alkyl groups. Semi-empirical calculations of the relative gas-phase stabilities of the proposed intermediate cations are useful in rationalising the observed chemistry.

  在用四氟硼酸亚硝酰进行某些α,β-不饱和酯的硝化反应中形成的活性中间体表现出高度活性α-羰基阳离子的预期行为。已观察到三种诊断性的反应类型，表明这些不稳定的阳离子的存在：（i）在Ritter反应中捕获，（ii）从丙基阳离子形成环丙烷，（iii）烷基的Wagner-Meerwein迁移。对所提出的中间阳离子的相对气相稳定性的半经验计算有助于合理化观察到的化学现象。
• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• [EN] THIENO[2,3-C]PYRANS AS CFTR MODULATORS<br/>[FR] THIÉNO [2,3-C] PYRANNES UTILISÉS EN TANT QUE MODULATEURS DU CFTR
  申请人：GALAPAGOS NV

  公开号：WO2015018823A1

  公开（公告）日：2015-02-12

  The present invention discloses compounds according to Formula I: Wherein R is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.

  本发明公开了根据式I的化合物：其中R如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予本发明化合物治疗囊性纤维化的方法。
• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：Galapagos NV

  公开号：US20150045327A1

  公开（公告）日：2015-02-12

  The present invention discloses compounds according to Formula I: wherein R 1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.

  本发明揭示了符合以下式I的化合物：其中R1如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予本发明化合物治疗囊性纤维化的方法。